company background image
CLVS.Q logo

Clovis Oncology OTCPK:CLVS.Q Stok Raporu

Son Fiyat

US$0.015

Piyasa Değeri

US$2.2m

7D

18.1%

1Y

-99.4%

Güncellenmiş

12 Jul, 2023

Veri

Şirket Finansalları

Clovis Oncology, Inc.

OTCPK:CLVS.Q Stok Raporu

Piyasa değeri: US$2.2m

CLVS.Q Stoklara Genel Bakış

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Daha fazla detay

CLVS.Q temel anali̇z
Kar Tanesi Skoru
Değerleme2/6
Gelecekteki Büyüme0/6
Geçmiş Performans0/6
Finansal Sağlık0/6
Temettüler0/6

Clovis Oncology, Inc. Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clovis Oncology
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$0.015
52 Haftanın En Yüksek SeviyesiUS$2.87
52 Haftanın En Düşük SeviyesiUS$0.01
Beta0.66
11 Aylık Değişim-40.00%
3 Aylık Değişim-28.57%
1 Yıllık Değişim-99.39%
33 Yıllık Değişim-99.77%
5 Yıllık Değişim-99.97%
Halka arzdan bu yana değişim-99.88%

Son Haberler & Güncellemeler

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10
These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Clovis Oncology Q2 2022 Earnings Preview

Aug 05

EMA recommends restricted use of Clovis cancer drug

Jul 22

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul 08

Clovis: Shifting Toward Nuclear Medicine

Apr 25

Clovis Oncology: Forging A Fresh Perspective

Mar 31

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24
News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22
How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31
What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Hissedar Getirileri

CLVS.QUS BiotechsUS Pazar
7D18.1%4.0%2.0%
1Y-99.4%18.0%32.4%

Getiri vs. Endüstri: CLVS.Q geçen yıl % 18 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: CLVS.Q geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CLVS.Q's price volatile compared to industry and market?
CLVS.Q volatility
CLVS.Q Average Weekly Movement61.3%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: CLVS.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CLVS.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 39% dan 61% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2009413Patrick Mahaffywww.clovisoncology.com

Clovis Oncology, Inc. Temel Bilgiler Özeti

Clovis Oncology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CLVS.Q temel i̇stati̇sti̇kler
Piyasa değeriUS$2.18m
Kazançlar(TTM)-US$251.91m
Gelir(TTM)US$133.02m

0.0x

P/S Oranı

0.0x

F/K Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CLVS.Q gelir tablosu (TTM)
GelirUS$133.02m
Gelir MaliyetiUS$31.59m
Brüt KârUS$101.43m
Diğer GiderlerUS$353.33m
Kazançlar-US$251.91m

Son Raporlanan Kazançlar

Sep 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-1.73
Brüt Marj76.25%
Net Kâr Marjı-189.37%
Borç/Özkaynak Oranı-158.0%

CLVS.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün